eptinezumab

Ahead of an expected uptick in news flow next month, Credit Suisse reviewed its ratings and price targets on the shares of several pharma companies, keeping in mind the fiscal year 2017 and the first-half of 2018. The firm downgraded shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:...

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is clinical-stage biopharmaceutical company whose lead pivotal-stage product candidate, eptinezumab, is used for the treatment of migraines. The company is also one that ordinary investors should consider passing on, according to CNBC's Jim...

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) hit a new 52-week low Wednesday for the second consecutive day as many investors found fault with the company's results from a phase 3 trial of its Eptinezumab therapy for the treatment of migraines. Piper Jaffray's Charles Duncan, Ph.D....

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) lost more than 20 percent on Tuesday and hit a new 52-week low of $13.80 despite reporting positive results for its late-stage migraine prevention drug called eptinezumab. Eptinezumab was successful in meeting the primary and key secondary...